Top

Nuclear Medicine and Molecular Imaging

Published in:

01-03-2015 | Original Article

Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast

Authors: I. Jo, Seok Kil Zeon, Sung Hoon Kim, Hae Won Kim, Sun Hee Kang, Sun Young Kwon, Su Jin Kim

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2015

Abstract

Purpose

The purpose of this study was to investigate the correlation of primary tumor FDG uptake to clinicopathological prognostic factors in invasive ductal carcinoma of the breast.

Methods

We retrospectively reviewed 136 of 215 female patients with pathologically proven invasive ductal breast cancer from January 2008 to December 2011 who underwent F-18 FDG PET/CT for initial staging and follow-up after curative treatment with analysis of estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2). The maximum standardized uptake value (SUVmax) of the primary breast tumor was measured and compared with hormonal receptor and HER2 overexpression status.

Results

The high SUVmax of primary breast tumors is significantly correlated with the clinicopathological factors: tumor size, histologic grade, TNM stage, negativity of ER, negativity of PR, HER2 overexpression and triple negativity. The recurrent group with non-triple negative cancer had a higher SUVmax compared with the non-recurrent group, though no significant difference in FDG uptake was noted between the recurrence and non-recurrent groups in subjects with triple-negative cancer. Lymph node involvement was the independent risk factor for cancer recurrence in the multivariate analysis.

Conclusions

In conclusion, high FDG uptake in primary breast tumors is significantly correlated with clinicopathological factors, such as tumor size, histologic grade, TNM stage, negativity of the hormonal receptor, HER2 overexpression and triple negativity. Therefore, FDG PET/CT is a helpful prognostic tool to direct the further management of patients with breast cancer.

Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Park EC, et al. Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat. 2011;43:12–8.CrossRefPubMedCentralPubMed

Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, et al. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer. 2012;15:197–202.CrossRefPubMedCentralPubMed

Yeo JS, Lee DS, Kang KW, Noh DY, Chung JK, Lee MC. Differential diagnosis of breast mass and staging of breast cancer using F-18-FDG PET. Nucl Med Mol Imaging. 1999;33:502–11.

Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of (18) F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol. 2014;6:177–91.CrossRefPubMedCentralPubMed

Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202:1316–29.CrossRefPubMed

Ian JR, Fiona H, Malcolm RK. FDG-PETCT in the staging of localregional metastases in breast cancer. Breast. 2011;20:491–4.CrossRef

Yoon JK. Clinical application of ¹⁸ F-FDG PET in breast cancer. Nucl Med Mol Imaging. 2008;42(Suppl):76–90.

Song BI, Hong CM, Lee HJ, Kang SM, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.CrossRefPubMedCentralPubMed

Kim JH, Yoo SW, Kang SR, Cho SG, Oh JR, Chong AR, et al. Prognostic significance of metabolic tumor volume measured by ¹⁸ F-FDG PET/CT in operable primary breast cancer. Nucl Med Mol Imaging. 2012;46:278–85.CrossRefPubMedCentralPubMed

10.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: NY, Springer; 2010. p. 347–69.

11.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol. 1991;19:403–10.CrossRef

12.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ. American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed

13.

Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14:1–103.CrossRef

14.

Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern cooperative oncology group companion study, EST 4189. J Clin Oncol. 2000;18:2059–69.PubMed

15.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.CrossRefPubMed

16.

Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and ¹⁸ F-FDG. AJR Am J Roentgenol. 2011;197:247–55.CrossRef

17.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and ER+, PR+, HER2- breast carcinoma using quantitative F-18 FDG PET imaging parameters. Cancer. 2008;112:995–1000.CrossRefPubMed

18.

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high ¹⁸ F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRefPubMed

19.

Kim BS, Sung SH. Usefulness of ¹⁸ F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26:175–83.CrossRefPubMed

20.

Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–27.CrossRefPubMed

21.

Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1830–8.CrossRefPubMed

22.

Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [¹⁸ F] FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–24.CrossRefPubMed

23.

Kong EJ, Chun KA, Cho IH, Lee SJ. ¹⁸ F-FDG PET/CT with contrast enhancement for evaluation of axillary lymph node involvement in T1 breast cancer. Nucl Med Mol Imaging. 2010;44:170–6.CrossRefPubMedCentralPubMed

24.

David G, Sylvie G, Jean-Luc M, Raphael P, Marc E, Jacqueline L, et al. Correlation of high ¹⁸ F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRef

25.

Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15:588–93.CrossRefPubMed

26.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using ¹⁸ F-fluorodeoxyglucose positron emission tomography /computed tomography fusion imaging (¹⁸ F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.CrossRefPubMed

27.

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–7.CrossRefPubMed

28.

Rebecca D, Maureen T, Kathleen P, Wedad H, Harriet K, Carol S, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.CrossRef

29.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.CrossRefPubMed

Title: Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast
Authors: I. Jo
Seok Kil Zeon
Sung Hoon Kim
Hae Won Kim
Sun Hee Kang
Sun Young Kwon
Su Jin Kim
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Nuclear Medicine and Molecular Imaging / Issue 1/2015
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-014-0296-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Usefulness of Additional SPECT/CT Identifying Lymphatico-renal Shunt in a Patient with Chyluria

Significance of Incidental Nasopharyngeal Uptake on 18F-FDG PET/CT: Patterns of Benign/Physiologic Uptake and Differentiation from Malignancy

RETRACTED ARTICLE: A Case Series of Four Patients With Clinically Significant Radiomicrosphere Pneumonitis After Yttrium-90 Radioembolization from the Perspective of Lung Dosimetry

Metastatic Neuroendocrine Tumour in a Renal Transplant Recipient: Dual-Tracer PET-CT with 18F-FDG and 68Ga-DOTANOC in This Rare Setting

Unusual Adrenal Gland Metastasis in a Patient with Follicular Carcinoma of the Thyroid Evidenced by 18F-FDG PET/CT and Confirmed by Biopsy

Usefulness of 131I-SPECT/CT and 18F-FDG PET/CT in Evaluating Successful 131I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii